公开(公告)号：US11434288B2

公开(公告)日：2022-09-06

申请号：US12412065

申请日：2009-03-26

Applicant: Yongzhang Luo ,  Hubing Shi

Inventor： Yongzhang Luo ,  Hubing Shi

IPC: G01N33/574 ,  A61K38/39 ,  C07K16/28

Abstract: The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules that specifically bind to nucleic acid molecules encoding Nucleolin. The present invention also discloses methods of screening for angiogenesis inhibitors which specifically interact with Nucleolin, and act as angiogenesis inhibitors in an analogous manner as Endostatin. In addition, the present invention discloses methods of inhibiting the proliferation of endothelial cells or angiogenesis of tumor by administering an anti-nucleolin antibody linked to a cytotoxic agent such as tumor necrosis factor alpha to the endothelial cells.

公开(公告)号：US10647968B2

公开(公告)日：2020-05-12

申请号：US14343694

申请日：2012-09-10

Applicant: Yongzhang Luo ,  Peng Liu ,  Xinan Lu ,  Yang Chen ,  Yan Fu ,  Guodong Chang ,  Daifu Zhou

Inventor： Yongzhang Luo ,  Peng Liu ,  Xinan Lu ,  Yang Chen ,  Yan Fu ,  Guodong Chang ,  Daifu Zhou

IPC: A61K38/18 ,  C12N9/14 ,  C07K14/475 ,  C12Q1/00 ,  A61K47/60

Abstract: The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.

公开(公告)号：US09364493B2

公开(公告)日：2016-06-14

申请号：US14008428

申请日：2012-03-28

Applicant: Yongzhang Luo ,  Yang Chen ,  Yan Fu ,  Lin Jia ,  Guodong Chang

Inventor： Yongzhang Luo ,  Yang Chen ,  Yan Fu ,  Lin Jia ,  Guodong Chang

IPC: A61K38/00 ,  A61K31/7048 ,  A61K38/39 ,  A61K39/395 ,  A61K9/00 ,  A61K9/127 ,  A61K47/48 ,  A61K31/065 ,  A61K31/718 ,  A61K45/06 ,  A61K31/365 ,  A61K31/724 ,  A61K38/17

CPC classification number: A61K31/7048 ,  A61K9/0019 ,  A61K9/127 ,  A61K31/065 ,  A61K31/718 ,  A61K38/1709 ,  A61K38/39 ,  A61K39/395 ,  A61K45/06 ,  A61K47/60 ,  A61K2300/00

Abstract: The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.

Abstract translation: 本发明涉及已知药物的新用途。 具体地，本发明涉及通过增加靶细胞对治疗剂的吸收来增强治疗剂的治疗功效的方法和组合物，并且特别涉及包含脂质筏/穴ol依赖性内吞调节剂的药物组合物 途径和一些治疗剂，例如抗肿瘤剂。 本发明还涉及一种能够增强抗肿瘤剂治疗功效的脂筏/穴ol石依赖性内吞途径调节剂的方法。

公开(公告)号：US20140335152A2

公开(公告)日：2014-11-13

申请号：US14008428

申请日：2012-03-28

Applicant: Yongzhang LUO ,  Yang CHEN ,  Yan FU ,  Lin JIA ,  Guodong CHANG

Inventor： Yongzhang LUO ,  Yang CHEN ,  Yan FU ,  Lin JIA ,  Guodong CHANG

IPC: A61K31/7048 ,  A61K47/48 ,  A61K31/365 ,  A61K38/17 ,  A61K31/724

CPC classification number: A61K31/7048 ,  A61K9/0019 ,  A61K9/127 ,  A61K31/065 ,  A61K31/718 ,  A61K38/1709 ,  A61K38/39 ,  A61K39/395 ,  A61K45/06 ,  A61K47/60 ,  A61K2300/00

Abstract: The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.

公开(公告)号：US08389684B2

公开(公告)日：2013-03-05

申请号：US12880265

申请日：2010-09-13

Applicant: Yongzhang Luo ,  Xiaomin Song ,  Xiaofeng Wang ,  Wei Zhuo ,  Guodong Chang ,  Yan Fu

Inventor： Yongzhang Luo ,  Xiaomin Song ,  Xiaofeng Wang ,  Wei Zhuo ,  Guodong Chang ,  Yan Fu

IPC: C07K1/00 ,  C07K14/00 ,  C07K17/00 ,  G01N33/00

CPC classification number: C07K16/30 ,  A61K39/39558 ,  A61K2039/505 ,  C07K14/4702 ,  C07K16/18 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/73 ,  G01N33/57415 ,  G01N33/57438 ,  G01N33/6893 ,  G01N2440/14 ,  Y10T436/25

Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence or metastasis of cancer by detecting plasma Hsp90α having the amino acid sequence of SEQ ID No. 1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.

Abstract translation: 本发明涉及癌症的诊断和治疗，具体涉及通过检测具有SEQ ID No.1的氨基酸序列的血浆Hsp90α作为肿瘤标记物来诊断癌症存在或转移的方法。 此外，本发明还涉及治疗癌症和转移的方法。

公开(公告)号：US20130023479A1

公开(公告)日：2013-01-24

申请号：US13554913

申请日：2012-07-20

Applicant: Yongzhang Luo ,  Wei Zhuo ,  Yan Fu ,  Guodong Chang

Inventor： Yongzhang Luo ,  Wei Zhuo ,  Yan Fu ,  Guodong Chang

IPC: G01N33/574 ,  A61K38/17 ,  A61P35/04 ,  C40B30/04

CPC classification number: G01N33/574 ,  A61K38/39 ,  C07K16/28 ,  C07K2317/76 ,  G01N2333/515 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/7014

Abstract: The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors or cancer suppressors, which function in a manner that is analogous to endostatin. The invention is based upon the discovery that nucleolin is specifically expressed on lymphangiogenic vessels and functions as a specific receptor for endostatin, and thus is involved in the signal transduction pathway of endostatin as an anti-lymphangiogenesis inhibitor. The present invention also discloses that cell surface nucleolin on lymphatic endothelial cells is a biomarker for lymphangiogenic vessels, which could be used for the prediction of tumor metastasis.

Abstract translation: 本发明涉及鉴定适合于抗淋巴管生成治疗以预防肿瘤生长和肿瘤转移的癌症受试者，特别是人类患者的方法。 本发明还涉及使用核仁林作为诱饵来搜索和筛选淋巴管生成抑制剂或癌抑制因子的新方法，其以类似于内皮抑素的方式起作用。 本发明基于以下发现：核仁林在淋巴管生成血管上特异性表达，并且作为内皮抑制素的特异性受体起作用，因此参与作为抗淋巴管生成抑制剂的内皮抑素的信号转导途径。 本发明还公开了淋巴管内皮细胞上的细胞表面核仁素是淋巴管生成血管生物标志物，可用于预测肿瘤转移。

公开(公告)号：US20100285103A1

公开(公告)日：2010-11-11

申请号：US12161477

申请日：2007-01-19

Applicant: Yongzhang Luo ,  Qing Han ,  Qingxin Lei ,  Guodong Chang ,  Yan Fu

Inventor： Yongzhang Luo ,  Qing Han ,  Qingxin Lei ,  Guodong Chang ,  Yan Fu

IPC: A61K9/127 ,  C07K14/78 ,  A61K9/52 ,  A61K9/00 ,  A61K9/14 ,  A61K38/39 ,  A61P35/00

CPC classification number: A61K38/40 ,  A61K38/363 ,  A61K38/38 ,  A61K47/60 ,  C07K14/78

Abstract: The present invention discloses an anti-tumor conjugate and pharmaceutical composition or kits comprising the conjugate, as well as a method of producing the anti-tumor conjugate. The anti-tumor conjugate of the present invention is metabolically stable in vivo, and is ultimately available for the treatment of tumors and production of anti-tumor medicaments.

Abstract translation: 本发明公开了抗肿瘤缀合物和包含该缀合物的药物组合物或试剂盒，以及产生抗肿瘤缀合物的方法。 本发明的抗肿瘤缀合物在体内代谢稳定，最终可用于治疗肿瘤和抗肿瘤药物的生产。

公开(公告)号：US07470667B2

公开(公告)日：2008-12-30

申请号：US11118109

申请日：2005-04-29

Applicant: Yongzhang Luo ,  Zhuobing Zhang ,  Qingxin Lei ,  Yan Sun ,  Jinwan Wang

Inventor： Yongzhang Luo ,  Zhuobing Zhang ,  Qingxin Lei ,  Yan Sun ,  Jinwan Wang

IPC: A61K38/00

CPC classification number: C07K14/78 ,  A61K38/00 ,  C07K2319/21

Abstract: The present invention provides methods of treating an angiogenesis-related disease of a subject using a therapeutically effective amount of a modified endostatin protein. In particular, the methods encompass treating an angiogenesis-related disease of a subject using a combination of the modified endostatin, and a known cancer therapy agent such as a chemotherapy agent, or a radiotherapy agent.

Abstract translation: 本发明提供使用治疗有效量的修饰的内皮抑素蛋白治疗受试者的血管发生相关疾病的方法。 特别地，所述方法包括使用修饰的内皮抑制素和已知的癌症治疗剂如化疗剂或放射治疗剂的组合来治疗受试者的血管生成相关疾病。

公开(公告)号：US20060058232A1

公开(公告)日：2006-03-16

申请号：US11118109

申请日：2005-04-29

Applicant: Yongzhang Luo ,  Zhuobing Zhang ,  Qingxin Lei

Inventor： Yongzhang Luo ,  Zhuobing Zhang ,  Qingxin Lei

IPC: A61K38/22 ,  A61K31/7072 ,  A61K31/337 ,  A61K33/24

CPC classification number: C07K14/78 ,  A61K38/00 ,  C07K2319/21

Abstract: The present invention provides methods of treating an angiogenesis-related disease of a subject using a therapeutically effective amount of a modified endostatin protein. In particular, the methods encompass treating an angiogenesis-related disease of a subject using a combination of the modified endostatin, and a known cancer therapy agent such as a chemotherapy agent, or a radiotherapy agent.

Abstract translation: 本发明提供使用治疗有效量的修饰的内皮抑素蛋白治疗受试者的血管发生相关疾病的方法。 特别地，所述方法包括使用修饰的内皮抑制素和已知的癌症治疗剂如化疗剂或放射治疗剂的组合来治疗受试者的血管生成相关疾病。